Silence Therapeutics Plc Net Income per Employee (SLN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Silence Therapeutics Plc  (NASDAQ: SLN)
 

Silence Therapeutics Plc Net Income per Employee

SLN's Quarterly Results, Trends, Rankings, Statistics
Silence Therapeutics Plc recorded a cumulative net loss of $-60 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 197 other companies achieving higher income per employee. While Silence Therapeutics Plc's total ranking has deteriorated compared to the previous quarter from 3622 to 3623.


What is Income per Employee Ratio?






SLN Net Income per Employee (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -681,284 -852,716 -1,006,955 -733,409 -899,159
SLN's Total Ranking # 3623 # 3622 # 3491 # 2647 # 3319
Seq. Net Income Change - - - - -


SLN Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 198
Healthcare Sector # 551
Overall Market # 3623

Net Income per Employee Statistics
High Average Low
$ -447,841 $ -958,584 $ -1,553,830
(Dec 31 2021)   (Jun 30 2025)







Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-08-31T19:03:44+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.